Clinical Trial Update: Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the efficacy and safety of Privigen in chronic inflammatory demyelinating polyneuropathy has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathy

Drugs mentioned

• Privigen (intravenous immunoglobulin (IVIG))

Snippet

Sponsor: CSL Behring | Conditions: Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | Status: COMPLETED | Results posted: 2013-04-04